How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?

• Published in: Current treatment options in neurology Vol. 19; no. 1; p. 3
• Main Authors: Horne, AnnaCarin, Wickström, Ronny, Jordan, Michael B., Yeh, E. Ann, Naqvi, Ahmed, Henter, Jan-Inge, Janka, Gritta
• Format: Journal Article
• Language: English
• Published: New York Springer US 2017
• Subjects: Critical Care Medicine; Diabetes; Family Medicine; General Practice; Intensive; Internal Medicine; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Neurologic Manifestations of Systemic Disease (N Scolding and C Rice; Neurologic Manifestations of Systemic Disease (N Scolding and C Rice, Section Editors); Neurology; Ophthalmology; Section Editors; Topical Collection on Neurologic Manifestations of Systemic Disease; Treatment; Hemophagocytic lymphohistiocytosis (HLH); Intrathecal treatment; Cerebrospinal fluid; Overall survival; Central nervous system (CNS); Neuroradiology; Long-term effects
• ISSN: 1092-8480; 1534-3138
• DOI: 10.1007/s11940-017-0439-4

Opinion statement Central nervous system (CNS)-hemophagocytic lymphohistiocytosis (HLH) is not a disease in itself, but it is part of a systemic immune response. The vast majority of patients with CNS-HLH also have systemic HLH and a large number of patients with primary and secondary HLH have CNS involvement. Reactivations within the CNS are frequent during the course of HLH treatment and may occur concomitant with or independent of systemic relapses. It is also important to consider primary HLH as an underlying cause of “unknown CNS inflammation” as these patients may present with only CNS disease. To initiate proper treatment, a correct diagnosis must be made. A careful review of the patient’s history and a thorough neurological examination are essential. In addition to the blood tests required to make a diagnosis of HLH, a lumbar puncture with cerebrospinal fluid (CSF) analysis and magnetic resonance imaging (MRI) should always be done in all cases regardless of the presence or absence of neurological signs or symptom. Treatment options for CNS-HLH include, but are not limited to, those commonly used in systemic HLH, including corticosteroids, etoposide, cyclosporine A, alemtuzumab, and ATG. In addition, intrathecal treatment with methotrexate and corticosteroids has become a standard care and is likely to be beneficial. Therapy must be initiated without inappropriate delay to prevent late effects in HLH. An interesting novel approach is an anti-IFN-gamma antibody (NI-0501), which is currently being tested. Hematopoietic stem cell transplantation (HSCT) also represents an important CNS-HLH treatment; patients with primary HLH may benefit from immediate HSCT even if there is active disease at time of transplantation, though care should be taken to monitor CNS inflammation through HSCT and treat if needed. Since CNS-HLH is a condition leading to the most severe late effects of HLH, early expert consultation is recommended.